Asparagine News and Research

RSS

Study provides insights into non-oncogenic addictions of tumors

Researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego have shown that tumors can ensure a more reliable nutrient supply by eliminating the p62 protein in surrounding stromal tissue.

9 Oct 2017

ERYTECH partners with Queen’s University to advance its product candidate for treating arginase-1 deficiency

ERYTECH Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Queen's University in Canada to advance the preclinical development of ERYTECH's eryminase program specifically for the treatment of arginase-1 deficiency, a rare and severe metabolic disorder related to arginine metabolism.

12 Jul 2017

Emory scientists show how same enzyme spurs Alzheimer's and Parkinson's disease

Alzheimer's disease and Parkinson's disease are not the same. They affect different regions of the brain and have distinct genetic and environmental risk factors.

4 Jul 2017

Enzyme identified in baker's yeast can efficiently annihilate leukemia cells

An enzyme identified in Saccharomyces cerevisiae, commonly known as brewer's or baker's yeast, has passed in vitro trials, demonstrating its capacity to kill acute lymphoblastic leukemia (ALL) cells.

18 Jan 2017

Researchers identify biomarkers to improve prognosis of CKD

Currently, there is no effective method to predict the prognosis of chronic kidney disease (CKD) patients.

27 Jul 2016

Researchers investigate why N14Y, N14K mutations have distinct effects in KID syndrome patients

A team of New York-based researchers has compared the effects of two disease-causing mutations, potentially explaining why patients with the rare genetic disorder keratitis-ichthyosis-deafness (KID) syndrome can experience different sets of symptoms.

28 Jun 2016

Arkin Holdings and Primera Capital lead investment of $13M in BioSight

BioSight, Ltd, an Israeli pharmaceutical development company focused on the development of innovative chemotherapy pro-drugs with reduced toxicity, announced today the closing of an investment of $13M led by the Mori Arkin's pharmaceutical investment firm, Arkin Holdings, and the US based venture firm Primera Capital. Proceeds of the financing will be used to fund a multi-center phase IIb clinical trial with the company's lead product, Astarabine™, for the treatment of AML.

16 May 2016

Food-based proteins can help address child malnutrition in developing countries

Contrary to popular belief among world relief workers, children in developing countries may not be eating enough protein, which could contribute to stunted growth, a Johns Hopkins-directed study suggests.

24 Feb 2016

Researchers submit patent application for drug that could destroy acute lymphoblastic leukemia

A patent application for a drug that could destroy the deadly childhood disease known as acute lymphoblastic leukemia — and potentially other cancers as well — has been submitted by researchers at Sandia National Laboratories, the University of Maryland and the MD Anderson Cancer Center in Houston.

14 May 2015

Sigma-Tau Rare Disease seeks EMA approval for use of Oncaspar for ALL treatment

Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.

10 Jul 2014

Scientists discover novel mechanism that influences GAS virulence at early steps of necrotizing fasciitis

How does Streptococcus pyogenes, or Group A streptococcus (GAS) — a bacterial pathogen that can colonize humans without causing symptoms or can lead to mild infections — also cause life-threatening diseases such as necrotizing fasciitis (commonly known as flesh-eating disease) and streptococcal toxic shock syndrome?

21 Jan 2014

Research may lead to potential treatment for deadly bacterial infections

Collaboration between the National University of Singapore (NUS) and The Hebrew University of Jerusalem (HUJ) on inflammation research may lead to a potential treatment for deadly bacterial infections

20 Jan 2014

Research opens way to possible new treatments for bacterial infections

How does Streptococcus pyogenes, or Group A streptococcus (GAS) - a bacterial pathogen that can colonize humans without causing symptoms or can lead to mild infections - also cause life-threatening diseases such as necrotizing fasciitis (commonly known as flesh-eating disease) and streptococcal toxic shock syndrome?

17 Jan 2014

ERYTECH proposes to broaden lead product in solid tumors, begins Phase II study in pancreatic cancer

ERYTECH Pharma (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, provides an update on its development plans to broaden the scope of its lead product ERYASP into the large field of solid tumors and announces the launch of a Phase II study in pancreatic cancer.

7 Jan 2014

Asparagine found in meat, eggs and dairy products is important for normal brain development

Asparagine, found in foods such as meat, eggs, and dairy products, was until now considered non-essential because it is produced naturally by the body. Researchers at the University of Montreal and its affiliated CHU Sainte-Justine Hospital found that the amino acid is essential for normal brain development.

26 Nov 2013

Scientists identify recessive gene mutation that reduces certain protein affecting brain development

Though worlds apart, four unrelated families have been united in a medical mystery over the source of a rare inherited disorder that results in their children being born with abnormal brain growth and severe functional impairments.

17 Oct 2013

AIBioTech announces implementation of L-asparaginase activity assay for pediatric ALL

AIBioTech is pleased to announce implementation of a new laboratory derived test to measure L-asparaginase levels in patients being treated with any of the current asparaginase drugs including: Oncaspar, Kidrolase, Erwinaze, and Elspar.

5 Feb 2013

Study investigates ability of bifidobacteria to remove glycans from milk glycoproteins

A research team at the University of California, Davis, has found that important and resourceful bacteria in the baby microbiome can ferret out nourishment from a previously unknown source, possibly helping at-risk infants break down components of breast milk.

15 Aug 2012

Positive results from ERYTECH Pharma asparaginase Phase II trials on ALL

The oral presentation will be held on June 17th 2012 by Prof. Dr. Hervé Dombret, Hospital Saint Louis, Paris (France) at the 17th Annual Meeting of European Hematology Association (EHA) in Amsterdam.

18 Jun 2012

Mod5 yeast prion contributes to cell survival under environmental stress

One of the greatest mysterious in cellular biology has been given a new twist thanks to findings reported in Science. Researchers at the RIKEN Brain Science Institute show that prions, proteins that transmit heritable information without DNA or RNA, can contribute to drug resistance and cellular adaptation. Their discovery of a yeast prion with these properties demonstrates the active role of the prion conversion in cellular fitness adaptation, providing new insights into the potentially broader function of prions in living organisms.

23 Apr 2012